In Vitro Assays for ADC Discovery: From Assay Design to Translational Insights

Please register via: https://us06web.zoom.us/webinar/register/WN_uemE0QlxRty1SigVzKxfVQ

Abstract:

Antibody-drug conjugates (ADCs) represent a powerful therapeutic modality for solid tumors and hematological malignancies. However, their development is often challenged by limited translational insights, narrow therapeutic windows, and the difficulty in differentiating new candidates from existing therapies.

This webinar will showcase how practical in vitro assay design can address key challenges for ADCs in oncology. We will introduce a set of bioassays, including cytotoxicity, bystander killing, internalization, and serum stability, to evaluate drug MOA, specificity, and potency. Real-world case studies will highlight how these data-driven approaches support candidate selection, enable clear differentiation of new candidates, and improve prediction of in vivo performance.

In this webinar, you will learn how to:

•      Design in vitro models and select appropriate cell lines to differentiate new ADC candidates

•      Apply core assays to define and optimize the therapeutic window

•       Leverage advanced analytical tools (high-content imaging, flow cytometry, IncuCyte, etc.) to generate robust, quantitative data

•      Turn assay results into practical insights to bridge discovery and translational studies

Speaker:

Zhuo Mao, PhD, Director of Bioassay, CRO Services, WuXi Biologics, is a seasoned in vitro biologist with over 15 years of experience in bioassays, specializing in ADC, antibody, and PROTACs discovery. He earned his Ph.D. in Biochemistry and Molecular Biology from National Institute of Biological Sciences, Beijing, and has led early discovery programs at multiple biotech companies. At WuXi Biologics, he serves as Director of the Bioassay group, and is responsible for the development, evaluation, and verification of cutting-edge cell-based assays, molecular biological assays, and immunoassays, as well as lead screening and characterization of therapeutic antibodies and ADCs.